Background {#Sec1}
==========

Biomarkers are important for guiding the diagnosis and treatment of cancer. Two broad groups comprise prognostic markers and predictive markers. Prognostic markers allow forecasts regarding the natural course of the disease. They differentiate between patients likely to have a good versus a poor outcome. By contrast, predictive markers provide upfront information regarding how likely a patient is to benefit from a specific treatment, and hence may guide the choice from available therapies. Anticipating treatment response or risk of treatment resistance is a critical need in cancer care. Relevant predictive markers mostly belong to the groups of drug targets, molecules associated with drug transport or metabolism, and regulators of apoptosis or DNA repair. As such, they are mechanistically involved in the drug response. In addition, because highly aggressive tumors are generally more difficult to manage than less aggressive ones, some prognostic indicators may also have predictive properties.

In the histopathologic assessment of breast cancer, the standard markers ER, PR, and HER2 identify drug targets, as ER-positive tumors are candidates for anti-estrogen treatment whereas HER2-positive tumors are candidates for treatment with trastuzumab. Further, the absence of all three marker molecules defines triple-negative breast cancers, which have a poor prognosis and limited treatment options. There is a lack of more refined predictive markers for treatment success in the disease.

In breast cancer, osteopontin is a biomarker for aggressiveness and for prognosis. Further, it has been described as a marker for treatment responses. Osteopontin causes breast cancer resistance to cyclophosphamide \[[@CR1]\], doxorubicin \[[@CR2]--[@CR4]\], paclitaxel \[[@CR4]\] and cisplatin \[[@CR4]\] through its anti-apoptotic properties or through the upregulation of drug exporters. Its levels also are an indicator for progression under anastrozole \[[@CR5]\]. According to two studies in a breast cancer model cell line, the suppression of osteopontin gene expression can enhance radiosensitivity and affect cell apoptosis, suggesting that the molecule may be a target for the improvement of radiotherapy \[[@CR6], [@CR7]\]. In all these cases, pan-osteopontin was measured. Osteopontin is subject to alternative splicing in cancer, and it is not known which splice form is responsible for conveying resistance to which specific treatment. The variant forms are distinguishable by antibodies to exon 4, recognizing osteopontin-a and osteopontin-b, or to the splice junction of osteopontin-c respectively. Here we test the association of osteopontin splice variants, expressed in the growths at the onset of cancer therapy, with the ensuing response to specific treatments.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study contained 119 patients from Poland who presented between 1995 and 2008 (allowing the assessment of 5-year survival). All cases refer to invasive ductal carcinoma, grades 1, 2 and 3, with subtypes including few mucinous and tubular carcinomas. Information about the patients was received from the Department of General and Oncological Surgery, Wroclaw and from the Division of Oncological Surgery, Walbrzych, Poland. The inclusion criteria were size of tumor not larger than 50 mm, and no adjuvant chemotherapy at the time of immunohistochemistry. For all patients, who met these criteria, paraffin blocks were available for evaluation. The data comprised also information about pathological TNM (pTNM), BRCA1 status, HER2, ER and PR status, and family history (other cases of invasive breast carcinoma in the family). Ensuing treatment constituted combinations of 1. hormone therapy with tamoxifen; 2. chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil) 6 courses every 28 days; 3. chemotherapy with AC (cyclophosphamide, doxorubicin) 4 courses every 21 days plus CMF 6 courses every 28 days; 4. radiotherapy to the chest (50 Gy; Mon-Fri 2 Gy) 5. radiotherapy to chest and axilla (50 Gy; Mon-Fri 2 Gy).

Immunohistochemistry {#Sec4}
--------------------

For each antibody a formalin-fixed and paraffin-embedded biopsy specimen from cancer tissue was cut on a microtome in 5 μm slices. The antibodies used in this study, after blocking in 2 % donkey serum, were anti-hOPNc IgY (Gallus Immunotech), and LF161 (Larry Fisher). The IgY antibody recognizes the osteopontin-c splice junction and detects the molecule in immunohistochemistry. It was diluted 1:500 to 1:700. The polyclonal rabbit antibody LF161 for staining selectively exon 4 (present in osteopontin-a and -b) was used at 1:1000. For each antibody, the tissues were scored for intensity (maximum intensity of the sample 0, 1, 2, or 3) and percent positivity (0, 1, 2, or 3), separately for nuclei and cytoplasm. The intensity of staining in immunohistochemistry was evaluated as previously described \[[@CR8]\] and the classification criteria of intensity followed a published source \[[@CR9]\]. The score was given as 0 points if no staining was observed, 1 for weak, 2 for moderate and 3 points for strong staining. Points were assigned to each case by two pathologists who independently evaluated all microscopic slides and in the rare cases of discrepant initial scores, a final score was agreed on after discussion \[[@CR8]\].

Statistics {#Sec5}
----------

All statistical analyses were performed using SAS (North Carolina, USA). Correlations between osteopontin-c and clinicopathological variables were assessed with Pearson's correlation test. Correlation coefficients of 0.1 to 0.3 are considered weak, 0.4-0.6 is moderate, and 0.7-0.9 is strong correlation. A *p*-value of 0.05 or lower indicates statistical significance. The primary methods for addressing the study purposes were Cox hazard models, logistic regression models, and the nonparametric Wilcoxon test. Odds ratios estimate the odds of death for a one-unit increase in the independent variable. Unadjusted odds ratios and 95 % confidence intervals were calculated to investigate the effects of the components of pathological scores on the odds of death. For survival under hormone therapy or chemotherapy, the biomarkers osteopontin-exon-4 and osteopontin-c were also analyzed in a multiple regression framework to adjust the effect for other covariates. Each model contained either osteopontin-exon-4 or osteopontin-c and each other biomarker (tumor size, lymph node involvement, grade, HER2, Progesterone Receptor, Estrogen Receptor, or BRCA1), added one-at-a-time. Cox hazard ratios, *p*-values, and Aikaike Information Criterion (AIC) were used.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

Of 119 patients, 46 women (39 %) died from breast cancer within 5 years while 73 women (61 %) were alive after this observation period. The average age at the time of immunohistochemistry was 53 years for non-survivors and 53 years for survivors. All patients, comprising both subgroups, underwent surgery consisting of either modified radical mastectomy with axillary dissection, or conservative breast surgery with axillary lymph node dissection and post-operative adjuvant therapy (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristicsn%T010.815949.623327.7365.0undefined2016.8N05848.711411.821613.43119.2undefined2016.8grade13630.326554.631815.1Her2low6958.0high2924.4undefined2117.6PR-6453.8+5445.4undefined10.8ER-5949.6+5949.6undefined10.8BRCA-1wild type5243.7mutant2621.8undefined4134.5familialno4437.0yes4033.6undefined3529.4chemotherapyAC 4 courses every 21 days, CMF 6 courses every 28 days3428.6CMF 6 courses every 28 days5546.2no3025.2radiation therapychest (50 Gy; Mon-Fri 2 Gy)4134.5chest/axilla (50 Gy; Mon-Fri 2 Gy)3126.1no4739.5hormone treatmentno5445.4tamoxifen6252.1The patient populations are described according to diverse clinical variables. *CMF* cyclophosphamide, methotrexate, fluorouracil, *AC* cyclophosphamide, doxorubicin

Immunohistochemistry {#Sec8}
--------------------

The anti-Osteopontin-exon-4 antibody, which recognizes osteopontin-a and -b, stained selectively the cytoplasm. Most tumors displayed osteopontin-c predominantly in their nuclei. The markers correlated moderately between each other (OPNc nuclear intensity, OPNc nuclear percent positivity, exon 4 cytoplasmic intensity, exon 4 cytoplasmic percent positivity), but in contrast to earlier studies they did not correlate with grade (Table [2](#Tab2){ref-type="table"}). Analysis for the association with survival by the markers under investigation (osteopontin-c, exon 4, tumor grade) reflected them as prognostic for outcome. In addition to analyzing the indicators in their original scale, we dichotomized the immunohistochemical biomarkers into low (0--1) or high (2--3). Only the logrank test for dichotomized osteopontin-c fell short of corroborating significance (Table [3](#Tab3){ref-type="table"}).Table 2Marker correlationsExon 4 cyt.per.Exon 4 cyt.int.OPNc nucl.per.OPNc nucl.int.Tumor gradeexon 4Pearson Correlation1**0.691150.411940.53769**0.10199cyt.per.*p*-value[\<0.0001\<0.0001\<0.0001]{.ul}0.2697exon 4Pearson Correlation10.31522**0.50491**0.21883cyt.int.*p*-value[0.0005\<0.0001]{.ul}*0.0168*OPNcPearson Correlation1**0.6636**0.0679nucl.per.*p*-value[\<0.0001]{.ul}0.4631OPNcPearson Correlation10.08674nucl.int.*p*-value0.3483tumor gradePearson Correlation1The table shows Pearson correlation coefficients and *p*-values for pairwise comparison of the histopathologic markers (osteopontin-c staining intensity, osteopontin-c percent positivity, exon 4 staining intensity, exon 4 percent positivity) and tumor grade. Statistical significance is indicated by underlining, moderate correlation is shown in boldTable 3Marker correlationsParametric (lognormal)LogrankWilcoxonχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueexon 4 intensity4.82[0.0281]{.ul}9.8692[0.0197]{.ul}16.3818[0.0009]{.ul}exon 4 high/low7.9144[0.0049]{.ul}15.5494[\<0.0001]{.ul}OPNc intensity7.24[\<0.0001]{.ul}16.9014[0.0007]{.ul}27.5348[\<0.0001]{.ul}OPNc high/low2.12340.14386.4847[0.0109]{.ul}tumor grade7.63[0.0057]{.ul}11.392[0.0098]{.ul}9.5087[0.0232]{.ul}Quantitative multivariable analysis and non-parametric tests for the prediction of survival by the markers under study (osteopontin-c, exon 4, tumor grade). Used were either the staining levels 0,1,2,3 (intensity) or the combination of 2 and 3 versus 0 and 1 (high/low) under various model assumptions. Underlined *p*-values are considered significant (*p* \< 0.05)

Cancer treatment {#Sec9}
----------------

The patients were subjected to various combinations of hormone treatment, chemotherapy, and radiation. Hormone treatment was tamoxifen. Chemotherapy comprised one of two regimens, CMF (cyclophosphamide, methotrexate, fluorouracil 6 courses every 28 days) or AC/CMF (cyclophosphamide, doxorubicin, 4 courses every 21 days plus CMF 6 courses every 28 days). Radiotherapy was given either to the chest (50 Gy; Mon-Fri 2 Gy) or to chest and axilla (50 Gy; Mon-Fri 2 Gy). Except for hormone therapy, survival after treatment (chemotherapy yes/no, radiation therapy yes/no) was shorter than survival without treatment. This reflects that more comprehensive therapy was given to patients with more aggressive cancers, which are inherently associated with poor prognoses for survival (Table [4](#Tab4){ref-type="table"}).Table 4Survival under treatmentYears of survivalTreatmentMeanstdnhormone no (all subgroups)6.483.9654hormone yes (all subgroups)7.444.3564hormone alone9.892.0018hormone and chemo6.634.3816hormone and radiation5.104.6310hormone, chemo, radiation7.104.8421chemo no (all subgroups)8.303.7930chemo yes (all subgroups)6.574.2289chemo alone7.924.5713chemo and hormone6.634.3816chemo and radiation5.823.6639chemo, hormone, radiation7.104.8421chemo (CMF 6 courses every 28 days)6.274.3655chemo (AC 4 courses every 21 days, CMF 6 courses every 28 days)7.064.0034radiation no (all subgroups)8.233.9047radiation yes (all subgroups)6.214.1772radiotherapy alone10.001.412radiation and hormone5.104.6310radiation and chemo5.823.6639radiation, chemo, hormone7.104.8421Shown are mean survival times in years (mean), standard deviation (std), and number of cases (n) consecutive to the various combinations of treatment. When censored for 13-year survivors (who may be alive beyond 13 years), the mean survival of patients under hormone treatment is 6.423 years with standard error 0.5274, compared to survival under no hormone treatment of 7.262 years and standard error 0.5077

Osteopontin variants and specific treatment regimens {#Sec10}
----------------------------------------------------

Tamoxifen is a selective estrogen receptor modulator that is used for the treatment of both early and advanced ER+ (estrogen receptor positive) breast cancers in pre- and post-menopausal women. Kaplan-Meier curves (Fig. [1](#Fig1){ref-type="fig"}) suggested a moderate survival benefit from treatment. When comparing hormone-treated to non-hormone-treated patients, low-grade cancers (grade 1) responded better to treatment than high-grade cancers (grade 2--3). In contrast, patients with high intensity staining (2--3) of exon 4 or osteopontin-c responded better to hormone therapy than those with low intensity staining (0--1) of these markers, as judged by a divergence with time between the hormone-treated and the non-hormone-treated patient groups at high marker intensity, but much less at low marker intensity.Fig. 1Kaplan-Meier survival curves for patients undergoing hormone therapy. Survival of patients under hormone treatment, distinguished according to low (levels 0--1) versus high (levels 2--3) osteopontin-c staining (top left), low versus high osteopontin-exon 4 staining (top right), or low (1) versus high (2--3) tumor grade (bottom left). The overall survival of patients receiving hormone treatment versus not receiving hormone treatment is shown for comparison on the bottom right. Untreated subgroups are displayed in black, treated subgroups in gray, low marker levels are shown as circles, high marker levels as triangles. The x-axis indicates years since diagnosis, the y-axis reflects % surviving patients

For the analysis of chemotherapy responses, the comparison to the non-chemotherapy treated group was not meaningful, because the survival of the treated group was lower, which is not reflecting harm caused by the treatment but indicates the circumstance that chemotherapy was given to patients with aggressive tumors and poor prognoses. The survival curves of patients undergoing chemotherapy (Fig. [2](#Fig2){ref-type="fig"}), when distinguished according to low (0--1) versus high (2--3) immunohistochemical markers, confirm the poor survival prognosis associated with exon 4 and osteopontin-c \[[@CR8]\], particularly reflected in a higher rate of patient deaths between 2 and 6 years after diagnosis in the high intensity group of each marker. Of note, the survival difference between exon 4 high and low appeared to be larger than between osteopontin-c high and low, implying the possibility that the marker could also be predictive of a poor chemotherapy response.Fig. 2Kaplan-Meier survival curves for patients undergoing chemotherapy. Survival of patients under chemotherapy, distinguished according to low (0--1, diamonds) versus high (2--3, triangles) immunohistochemical markers. Shown are Kaplan Meier curves for osteopontin-c (top panel) or exon 4 (middle panel). For comparison, the survival of all patients treated (gray markers) or not treated (black markers) with chemotherapy is displayed (bottom panel). The x-axis indicates years since diagnosis, the y-axis reflects % surviving patients

The Kaplan Meier survival curves of patients undergoing radiation treatment, distinguished according to low (0--1) versus high (2--3) immunohistochemical markers, again confirm the poor survival associated with exon 4 and osteopontin-c. Although the curves converge after about 10 years, during 2--6 years substantially more patients die in the high marker intensity groups than in the low marker intensity groups (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Kaplan-Meier survival curves for patients undergoing radiotherapy. Survival of patients under radiotherapy, distinguished according to low (0--1, diamonds) versus high (2--3, triangles) immunohistochemical markers. Shown are Kaplan Meier curves for osteopontin-c (top panel) or exon 4 (middle panel). For comparison, the survival of all patients receiving radiation (gray markers) or not treated with radiation (black markers) is displayed (bottom panel). The x-axis indicates years since diagnosis, the y-axis reflects % surviving patients

Osteopontin variants as predictive markers {#Sec11}
------------------------------------------

The above findings (reduced survival of high versus low exon 4 and osteopontin-c under chemotherapy or radiation therapy) can be interpreted as poor therapy responses only if they are a) significant and b) distinct from the overall prognostic nature of these markers, as previously reported \[[@CR8], [@CR10], [@CR11]\]. The seemingly favorable survival of high versus low exon 4 and osteopontin-c under hormone therapy is distinct from the prognostic characteristic, but requires testing for significance \[[@CR12]\].

Cox hazard ratios (Table [5](#Tab5){ref-type="table"}) showed that the staining intensity for osteopontin exon 4 was negatively correlated with survival in the non-hormone treated group, but not in the hormone treated group. This is consistent with a favorable response to tamoxifen associated with the presence of osteopontin exon 4. By contrast, osteopontin exon 4 was associated with a poor response to chemotherapy according to reduced survival by high level expressors in the treated group, but not in the non-chemotherapy treated group. CMF (not AC/CMF) was the regimen, the efficacy of which was compromised by high osteopontin exon 4. Because a supremum test indicated low confidence in the proportionality assumption, we sought to independently corroborate the analysis using the logrank and Wilcoxon tests (Table [6](#Tab6){ref-type="table"}). According to all 3 tests, exon 4 is predictive of resistance to chemotherapy with CMF (as judged by significantly worse survival of the high marker intensity group), but not with AC/CMF. According to Cox hazard ratios and logrank test, exon 4 is a predictor of a favorable response to hormone therapy (the significantly worse survival associated with high marker intensity in the non-hormone treated group is lost under hormone therapy with tamoxifen). Although a similar predictive potential (for a favorable response to hormone therapy) is implied for osteopontin-c, the *p*-values for the Cox and logrank tests in the "hormone no" group fall just short of statistical significance.Table 5Survival under specific treatmentsExon 4 intensityExon 4 %OPN-c intensityOPN-c %TreatmentnOdds ratio95 % CI*p*-valueSupre-mum testOdds ratio95 % CI*p*-valueSupre-mum testOdds ratio95 % CI*p*-valueSupre-mum testOdds ratio95 % CI*p*-valueSupre-mum testhormone no (all subgroups)540.503**0.287-0.881**[0.016]{.ul}0.1041.0870.624-1.8950.7670.9080.6200.353-1.0890.0960.1781.2100.696-2.1020.5000.954hormone yes (all subgroups)650.6570.381-1.1340.131*\<.0001*0.6870.391-1.2060.1910.0560.8260.463-1.4730.517*0.005*1.1010.630-1.9230.7350.704hormone alone181.5340.430-5.4670.5090.6141.1220.420-2.9980.8190.6161.6610.607-4.5420.3230.5181.1130.383-3.2350.8450.607hormone and chemo160.4120.129-1.3160.134*0.022*0.6370.173-2.3430.4970.0640.6340.204-1.9730.432*0.049*1.3520.441-4.1480.5980.269hormone and radiation100.3580.069-1.8620.2220.1800.4950.096-2.5580.4010.5680.2500.029-2.1800.2090.1850.8270.192-3.5610.7980.597hormone, chemo, radiation210.5980.169-2.1120.4240.7630.6040.218-1.6760.3330.8010.8670.278-2.7100.8060.3750.8940.310-2.5800.8360.810chemo no (all subgroups)300.7110.320-1.5800.403*0.025*0.7940.366-1.7220.5600.2330.9030.391-2.0840.8110.1340.9780.425-2.2540.9590.612chemo yes (all subgroups)890.582**0.371-0.913**[0.019]{.ul}*0.001*0.8730.552-1.3830.5640.5200.6940.439-1.0980.119*0.003*1.1810.754-1.8480.4680.327chemo (CMF)550.524**0.290- 0.943**[0.031]{.ul}*0.008*0.7270.403-1.3140.2910.6930.7060.391-1.2760.249*0.013*1.1130.626-1.9790.7150.337chemo (AC/CMF)340.6880.338-1.4000.3020.1441.2520.596-2.6320.5530.5430.6810.329-1.4100.3010.1211.2800.608-2.6940.5150.727chemo alone130.4180.111-1.5740.1970.7631.2070.367-3.9710.7570.6370.7110.205-2.4680.592*0.047*1.2000.362-3.9800.7660.560chemo and radiation390.5460.285-1.0470.069*0.027*1.3430.686-2.6290.3890.4490.6230.320-1.2130.1640.4441.2150.641-2.3040.5510.950radiation no (all subgroups)470.6470.333-1.2590.200*0.024*0.9730.519-1.8240.9330.2030.9810.527-1.8260.9510.1051.4000.746-2.6270.2940.404radiation yes (all subgroups)720.6260.376-1.0440.073*0.002*0.7740.466-1.2850.3210.4890.6750.394-1.1570.153*0.036*1.0860.659-1.7910.7450.832Cox hazard ratios. The immunohistochemistry results for osteopontin-c and exon 4 were categorized into high staining (path scores 2 and 3) or low staining (path scores 0 and 1). Significant *p*-values are underlined, and confidence intervals that do not contain 1.0 are shown in bold. The last column displays the *p*-value for the supremum test, which assesses the proportionality assumption. *p*-values in italics are significant and indicate low confidence in the proportionalityTable 6Survival under specific treatmentsExon 4 intensityExon 4 %OPN-c intensityOPN-c %LogrankWilcoxonLogrankWilcoxonLogrankWilcoxonLogrankWilcoxonTreatmentnχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valueχ^2^*p*-valuehormone no (all subgroups)547.127[0.008]{.ul}9.087[0.003]{.ul}0.1060.7450.0150.9023.3840.0665.373[0.021]{.ul}0.5510.4580.3720.542hormone yes (all subgroups)652.6310.1056.981[0.008]{.ul}1.9700.1603.2670.0710.4800.4892.2180.1360.1300.7190.1400.708hormone alone180.5910.4420.2260.6350.0690.7930.0710.7901.3030.2540.9610.3270.0500.8230.1840.668hormone and chemo162.6130.1063.937[0.047]{.ul}0.5310.4661.0710.3010.7070.4011.7780.1820.3170.5730.1010.751hormone and radiation101.8330.1762.7090.1000.8370.3600.9870.3202.0490.1522.4850.1150.0750.7840.0110.915hormone, chemo, radiation210.7030.4020.6010.4381.0360.3091.1390.2860.0650.7990.2400.6240.0470.8290.0890.765chemo no (all subgroups)300.8330.3613.4720.0620.4030.5261.1230.2890.0670.7950.4650.4950.0030.9550.0490.825chemo yes (all subgroups)896.588[0.010]{.ul}10.593[0.001]{.ul}0.3870.5340.5660.4522.8580.0917.465[0.006]{.ul}0.6140.4330.1860.667chemo (CMF)555.455[0.020]{.ul}9.345[0.002]{.ul}1.2750.2591.5610.2121.5220.2174.847[0.028]{.ul}0.1520.6970.0160.899chemo (AC/CMF)341.2890.2561.6080.2050.4200.5170.3170.5741.3000.2542.7400.0980.5070.4770.4560.500chemo alone131.8650.1721.2680.2600.1070.7430.2450.6200.3220.5701.3560.2440.0990.7530.1260.722chemo and radiation394.123[0.042]{.ul}8.229[0.004]{.ul}0.8980.3440.2090.6482.3800.1233.2710.0710.4310.5120.1800.672radiation no (all subgroups)471.9640.1613.6380.0570.0090.9270.0670.7960.0050.9460.4970.4811.3100.2521.8190.178radiation yes (all subgroups)723.7860.0528.444[0.004]{.ul}1.1430.2851.6900.1942.3950.1224.766[0.029]{.ul}0.1220.7270.0900.764Logrank test and Wilcoxon test for the prediction of survival by the dichotomized immunohistochemical markers in the indicated subgroups of patients. Significant *p*-values are underlined

To assess whether the prediction of treatment responses can be strengthened when additional readouts are considered, we performed multivariate analysis. For survival with or without hormone therapy, exon 4 staining or osteopontin-c staining were analyzed as predictors in conjunction with other covariates (Table [7](#Tab7){ref-type="table"}). Whereas osteopontin-c did not improve as a predictor, the combination of high exon 4 intensity plus high tumor grade worsened the prognosis without hormone therapy (exon 4 alone hazard ratio 0.503, *p*-value 0.016; with grade 0.450, 0.007), but maintains the favorable prognosis under treatment (exon 4 alone 0.657, 0.131; with grade 0.763, 0.352). Hazard ratios and *p*-values for survival under CMF chemotherapy showed improvement for the prediction with the combination of exon 4 intensity plus HER2 (0.398, 0.009), compared to exon 4 intensity alone (0.524, 0.019). Low HER2 and high staining intensity for osteopontin exon 4 increase the likelihood for resistance to CMF chemotherapy (Table [8](#Tab8){ref-type="table"}).Table 7Multivariate analysisHazard ratios and *p*-values for survival under hormone therapy, using exon 4 staining (0--1 = low, 2--3 = high) or osteopontin-c staining (0--1 = low, 2--3 = high) plus other readouts as covariates. The combination of exon 4 intensity plus grade, which strengthens the prediction compared to exon 4 intensity alone, is boxedTable 8Multivariate analysisHazard ratios and *p*-values for survival under chemotherapy, using exon 4 staining (0--1 = low, 2--3 = high) plus other readouts as covariates. The combination of exon 4 intensity plus HER2, which strengthens the prediction compared to exon 4 intensity alone, is boxed. Tumor grade was included as low (grade 1) or high (grades 2--3). The parameters for tumor size and lymph node involvement, were not dichotomized and had different hazard ratios for each level (not shown). Significant *p*-values (*p* \< 0.05) are underlined

Discussion {#Sec12}
==========

In this study, we have identified osteopontin exon 4 as a predictor for a favorable treatment response to tamoxifen (the staining intensity is negatively correlated with survival in the non-hormone treated group, but not in the hormone treated group), but for resistance to chemotherapy with CMF (high level expressors have reduced survival in the treated group, but not in the non-treated group). The combination of high staining for osteopontin exon 4 with HER2 negative status appears to increase the likelihood for chemotherapy resistance. By contrast, osteopontin-c is prognostic, but may not be predictive for the therapeutic regimens applied here. Notably, while osteopontin-c is not a predictor of survival in the hormone treated group, a trend for it to be negatively associated with survival time in the non-hormone treated group fell just short of indicating significance by Cox hazard ratio (*p* = 0.096) and logrank test (*p* = 0.066), while significance was attained with the Wilcoxon test (*p* = 0.021). Nevertheless, in multivariate analysis no improvement was achieved for prediction with osteopontin-c. It is therefore more likely that a favorable response to hormone therapy is encoded in an osteopontin-a specific domain than in a common domain of osteopontin. The resistance to chemotherapy is selective to exon 4. As osteopontin-b is barely expressed in breast cancer and the protein is rapidly degraded \[[@CR13]\], it is implied that osteopontin-a is the splice form responsible for resistance to chemotherapy.

The favorable response to anti-estrogens by breast cancers with high osteopontin-a levels may reflect the property of the osteopontin gene as a sentinel for estrogen responsiveness in mammary cells. Although an estrogen-response element is not present in the promoter, there are 7 steroid factor-response element-like sequences in this region. Expression may be induced by estrogen via ERRα in a context-dependent manner \[[@CR14], [@CR15]\]. Tumors with high levels of osteopontin-a probably are highly sensitive to estrogen signals (mediated through ER or through ERR), and therefore will be more likely to be susceptible to tamoxifen treatment. In immunohistochemistry, the abundance of osteopontin may be more accurately reflected in staining intensity than in percent positivity, because the percentage of area stained is much more susceptible to the placement of the section than is the intensity, making the former a weaker readout. In a related setting, for ER in breast cancer, it has been shown that the threshold of immunoreactivity is more important than the percentage positive in the generation of discordant or false-negative assays \[[@CR16]\].

The abundance of exon 4 is predictive of resistance to chemotherapy with CMF, but not with AC/CMF. This was initially surprising as osteopontin was not previously known to convey resistance to methotrexate or fluorouracil. In contrast, the two AC agents, doxorubicin (adriamycin) and cyclophosphamide, have been reported to be subject to osteopontin-mediated drug resistance. The finding may point to translational limitations for testing drug sensitivity with mono-therapy in cell culture, as was done in the published resistance studies \[[@CR1]--[@CR4]\]. It may also be reflective of the benefit conveyed with altering drug combinations over treatment cycles, not only to alleviate toxicity but also to enhance efficacy. By broadening and alternating the drug regimen, the response to treatment in our breast cancer patients could be enhanced.

Discrepancies between this study and previous reports that had indicated an association between osteopontin levels and radiation resistance require an explanation. We see three likely causes. a) While the regimens tested here had overlap with the ones earlier associated with resistance, the treatments were complex and included components that may have helped to overcome resistance. Most patients in this study received radiation in conjunction with hormone therapy and/or chemotherapy. b) Overall, the efficacies of radiation treatment were low, reflected in poor survival in the treated groups. The underlying reason is that more aggressive treatment is given to patients with worse prognosis and could be interpreted to mean that all patients receiving radiation were in essence resistant. Therefore, no differences were discernible between the marker (osteopontin-c or exon 4) high and low groups. c) It is possible that the observations of this study may be compromised by its moderate power (119 patients). We previously reported that osteopontin-c is correlated to tumor grade \[[@CR13]\] and the combination of both readouts slightly improves the prediction of survival \[[@CR8]\]. In the present study, no correlation was identified between osteopontin-c and tumor grade or exon 4 and tumor grade, which may be attributable to the limited group size. The lack of significance for predicting survival by dichotomized osteopontin-c in the logrank test might seem to support this possibility.

Beside breast cancer, pan-osteopontin levels have been associated with treatment responses of prostate cancer to taxanes/androgen deprivation \[[@CR17]\], of lung cancer (NSCLC) to carboplatin/paclitaxel \[[@CR18]\], and of colorectal cancer to FOLFIRI-bevacizumab \[[@CR19]\] (as osteopontin interacts with VEGF in multiple ways \[[@CR20]\] it would be expected to affect the response to bevacizumab). In some of the predecessor studies, however, it has not been clear whether osteopontin was functionally linked to a reduced treatment response or independently predicted poor survival, because tumors with higher levels of the biomarker are more aggressive and inherently have a bad prognosis. A mechanistic connection of pan-osteopontin to drug resistance was established in prostate cancer. Osteopontin binds to integrin α~v~β~3~ and concentration- and time-dependently upregulates the efflux transporter ABCB1 (P-glycoprotein, PGP), which causes resistance to drugs that are substrates for this transporter \[[@CR21]\]. Similarly in breast tumor cells, osteopontin may activate the hedgehog pathway and enhance drug resistance through GLI1-dependent regulation of ABCB1 and ABCG2 \[[@CR4]\].

Conclusions {#Sec13}
===========

In conclusion, immunohistochemistry of osteopontin splice variants has potential to aid decision making in breast cancer treatment. Specifically, osteopontin exon 4 is associated with a favorable response to tamoxifen, but a poor response to chemotherapy with CMF (cyclophosphamide, methotrexate, fluorouracil). While being prognostic, osteopontin-c may not be a significant predictor for sensitivity to treatment.
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